Key result
African Americans show no difference in avoidable CHF hospitalizations despite receiving fewer beta blockers and ACEi/ARBs.
Why the study?
Equitable access to health insurance coverage may improve outcomes and mitigate racial/ethnic disparities in congestive heart failure treatment and outcomes among TRICARE beneficiaries.
Does race/ethnicity affect the receipt of pharmacological therapy and the likelihood of potentially avoidable hospitalizations in TRICARE beneficiaries with congestive heart failure?
Cohort (n=2,183)
Does race/ethnicity affect the receipt of pharmacological therapy and the likelihood of potentially avoidable hospitalizations in TRICARE beneficiaries with congestive heart failure?
In an equal-access healthcare system (TRICARE), racial disparities in the prescription of heart failure medications exist but do not result in disparities in potentially avoidable hospitalizations.
Answers are grounded in this paper and cite their sources.
Medication disparities did not increase avoidable HF hospitalizations in TRICARE; leaves open generalizability and causality in other systems.
BACKGROUND: Equitable access to health insurance coverage may improve outcomes of care for chronic health conditions and mitigate racial/ethnic health disparities. This study examines racial/ethnic disparities in the treatment and outcomes of care for TRICARE beneficiaries with congestive heart failure (CHF). METHODS: Using a retrospective cohort analysis, we examined demographic characteristics, sources of care, and comorbid conditions for 2183 beneficiaries of the Military Health System's TRICARE program (representing 115,584 beneficiaries after adjusting for survey weights) with CHF. Treatments included use of CHF-related medications, while the outcome of interest was any CHF-related potentially avoidable hospitalizations (PAHs). RESULTS: While African Americans were less likely than whites to have received beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers following a CHF diagnosis (P<0.0001). Hispanics were, in some cases, equally likely as whites to receive pharmacological treatments for CHF. In multivariate models, there were no significant racial/ethnic differences in the odds of a PAH; age greater than 65 was the most significant predictor of a PAH. CONCLUSIONS: This study suggests that although there are some racial and ethnic disparities in the receipt of pharmacological therapy for CHF among TRICARE beneficiaries, these differences do not translate into disparities in the likelihood of a PAH. The findings support previous research suggesting that equal access to care may mitigate racial/ethnic health disparities.
No takes yet. Share an insight, caveat, or question.
Bagchi et al. (2011) conducted a cohort in Congestive heart failure (CHF) (n=2,183). Race/Ethnicity (African American and Hispanic) vs. White race was evaluated on Any CHF-related potentially avoidable hospitalizations (PAHs). Although African American beneficiaries were less likely than whites to receive beta blockers and ACE inhibitors/ARBs, there were no significant racial/ethnic differences in the odds of a potentially avoidable hospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: